These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8488764)

  • 21. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
    Thürlimann B; Morant R; Jungi WF; Radziwill A
    Support Care Cancer; 1994 Jan; 2(1):61-5. PubMed ID: 8156259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
    Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
    Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonate treatment of lytic bone metastases.
    Lipton A; Berenson JR
    Drugs Aging; 1999 Apr; 14(4):241-6. PubMed ID: 10319239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Two bedridden patients with bone metastases from breast cancer effectively treated with pamidronate therapy].
    Kokufu I; Taniguchi H; Kim YH; Fukuda K; Yamamoto M; Yano T; Yamada K; Kitano H
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1751-4. PubMed ID: 11057329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
    Conte PF; Giannessi PG; Latreille J; Mauriac L; Koliren L; Calabresi F; Ford JM
    Ann Oncol; 1994; 5 Suppl 7():S41-4. PubMed ID: 7873461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biosphonates in oncology].
    Paule B; Clerc D; Brion N
    Presse Med; 2000 Apr; 29(13):723-9. PubMed ID: 10797827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
    Coleman RE; Woll PJ; Miles M; Scrivener W; Rubens RD
    Br J Cancer; 1988 Nov; 58(5):621-5. PubMed ID: 3219273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bisphosphonates in the treatment and prevention of bone metastases].
    Hoekman K; van Holten-Verzantvoort AT; Pinedo HM
    Ned Tijdschr Geneeskd; 1997 Nov; 141(46):2217-22. PubMed ID: 9550782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The evaluation of pamidronate therapy for bone metastases from breast cancer].
    Nomizu T; Yabuta T; Katagata N; Watanabe F; Yamaki Y; Nihei M; Tsuchiya A; Takenoshita S; Abe R
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2097-103. PubMed ID: 11103241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
    Tyrrell CT; Bruning PF; May-Levin F; Rose C; Mauriac L; Soukop M; Ford JM
    Eur J Cancer; 1995 Nov; 31A(12):1976-80. PubMed ID: 8562151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral bisphosphonates: A review of clinical use in patients with bone metastases.
    Major PP; Lipton A; Berenson J; Hortobagyi G
    Cancer; 2000 Jan; 88(1):6-14. PubMed ID: 10618600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.
    Wang RF; Zhang CL; Zhu SL; Zhu M
    Med Princ Pract; 2003; 12(2):97-101. PubMed ID: 12634464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
    N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.
    Vitale G; Fonderico F; Martignetti A; Caraglia M; Ciccarelli A; Nuzzo V; Abbruzzese A; Lupoli G
    Br J Cancer; 2001 Jun; 84(12):1586-90. PubMed ID: 11401309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.
    Yeh DC; Chen DR; Chao TY; Chen SC; Wang HC; Rau KM; Feng YH; Chang YC; Lee KD; Ou-Yang F; Kuo WH; Chang KJ; Lin YC; Tseng LM; Hou MF
    In Vivo; 2014; 28(5):1001-4. PubMed ID: 25189922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.